Diaceutics and London Genetics partner to accelerate biomarker development in the global biopharmaceutical industry
The new software is expected to be launched in 2011 and will be based on the Diaceutics Fusion platform and the London Genetics Biomarker Pathway platform
Register for free to listen to this article
Listen with Speechify
0:00
5:00
WASHINGTON, D.C. and LONDON—Diaceutics Limited, an international change management and consulting firm specializing in personalized medicine, and London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, have forged a strategic partnership to develop software decision tools for biopharmaceutical companies.
The tools are intended to help such companies gain rapid and extensive access to the world's leading academic biomarker research groups, and they reportedly will enable commercial biomarker research teams to comprehensively explore global biomarker resources available to identify genes and gene sequences, as well as connect with the researchers and clinicians relevant to their targeted therapy research.
"We are delighted to partner with London Genetics, leverage their biomarker expertise, and together build tools that will address a key problem for therapy development teams," says Peter Keeling, CEO of Diaceutics. "Biomarker research is often limited because teams don't know the capabilities of external research centers and miss potential collaborations which could accelerate their targeted therapy development."
The new software, which is expected to be launched in 2011, is based on the Diaceutics Fusion platform, a personalized medicine planning software application for targeted therapy development teams, and the London Genetics Biomarker Pathway platform. The tools to be developed under the strategic partnership will allow research teams to build biomarker hypotheses, request expressions of interest and prepare proposals for clinical development. The expressions of interest, requesting access to patient samples and investigator networks, will be sent to academic biomarker research teams globally, including London Genetics' own network of over 3,000 investigators in a broad range of therapeutic areas and technology disciplines. In this way, partners can be rapidly identified and collaborative projects instigated.
"This strategic alliance with Diaceutics fits closely with our overall goal to expedite pharmacogenetic and biomarker partnerships between industry and academia for more effective targeted drug development," notes Dominique Kleyn, CEO of London Genetics. "We look forward to working with new industry partners identified via the tools we are developing with Diaceutics."
The tools are intended to help such companies gain rapid and extensive access to the world's leading academic biomarker research groups, and they reportedly will enable commercial biomarker research teams to comprehensively explore global biomarker resources available to identify genes and gene sequences, as well as connect with the researchers and clinicians relevant to their targeted therapy research.
"We are delighted to partner with London Genetics, leverage their biomarker expertise, and together build tools that will address a key problem for therapy development teams," says Peter Keeling, CEO of Diaceutics. "Biomarker research is often limited because teams don't know the capabilities of external research centers and miss potential collaborations which could accelerate their targeted therapy development."
The new software, which is expected to be launched in 2011, is based on the Diaceutics Fusion platform, a personalized medicine planning software application for targeted therapy development teams, and the London Genetics Biomarker Pathway platform. The tools to be developed under the strategic partnership will allow research teams to build biomarker hypotheses, request expressions of interest and prepare proposals for clinical development. The expressions of interest, requesting access to patient samples and investigator networks, will be sent to academic biomarker research teams globally, including London Genetics' own network of over 3,000 investigators in a broad range of therapeutic areas and technology disciplines. In this way, partners can be rapidly identified and collaborative projects instigated.
"This strategic alliance with Diaceutics fits closely with our overall goal to expedite pharmacogenetic and biomarker partnerships between industry and academia for more effective targeted drug development," notes Dominique Kleyn, CEO of London Genetics. "We look forward to working with new industry partners identified via the tools we are developing with Diaceutics."
